At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRCT PROCEPT BioRobotics
Closed 06-03 16:00:00 EDT
26.33
-0.43
-1.61%
盘后25.79
-0.54-2.04%
19:57 EDT
High26.66Low25.95Vol732.92K
Open26.56D1 Closing26.76Amplitude2.65%
Mkt Cap1.50BTradable Cap1.41BTotal Shares56.91M
T/O19.27MT/O Rate1.37%Tradable Shares53.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

PROCEPT BioRobotics (PRCT) Receives a Buy from TD Cowen
TIPRANKS  ·  06-01 13:35
PROCEPT BioRobotics (PRCT) Receives a Buy from TD Cowen
Procept Biorobotics® Advances Prostate Cancer Program With Water Iv Study Enrollment Completion and Expanded Ide Approval
THOMSON REUTERS  ·  05-28
Procept Biorobotics® Advances Prostate Cancer Program With Water Iv Study Enrollment Completion and Expanded Ide Approval
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
GlobeNewswire  ·  05-28
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
A Look At PROCEPT BioRobotics (PRCT) Valuation After Its Better Than Expected Q1 Earnings And Analyst Updates
Simply Wall St.  ·  05-27
A Look At PROCEPT BioRobotics (PRCT) Valuation After Its Better Than Expected Q1 Earnings And Analyst Updates
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
TIPRANKS  ·  05-14
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
Should PROCEPT BioRobotics’ Reaffirmed 2026 Outlook Amid Wider Losses Require Action From PRCT Investors?
Simply Wall St.  ·  05-11
Should PROCEPT BioRobotics’ Reaffirmed 2026 Outlook Amid Wider Losses Require Action From PRCT Investors?
Procept BioRobotics EVP, CTO Barry Templin files initial beneficial ownership statement
Reuters  ·  05-01
Procept BioRobotics EVP, CTO Barry Templin files initial beneficial ownership statement
Procept BioRobotics to present at Bank of America Health Care Conference
Reuters  ·  05-01
Procept BioRobotics to present at Bank of America Health Care Conference
PROCEPT BioRobotics Price Target Raised to $35.00/Share From $28.00 by Piper Sandler
Dow Jones  ·  05-01
PROCEPT BioRobotics Price Target Raised to $35.00/Share From $28.00 by Piper Sandler
Stock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance
Stock Track  ·  04-30
Stock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance
Procept Biorobotics Corp : Piper Sandler Raises Target Price to $35 From $28
THOMSON REUTERS  ·  04-30
Procept Biorobotics Corp : Piper Sandler Raises Target Price to $35 From $28
PROCEPT BioRobotics: Buy Rating Reaffirmed on Strong Q1 Performance and Multi‑Year Outlook, Price Target Unchanged at $34
TIPRANKS  ·  04-30
PROCEPT BioRobotics: Buy Rating Reaffirmed on Strong Q1 Performance and Multi‑Year Outlook, Price Target Unchanged at $34
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Alterity Therapeutics (OtherPRNAF)
TIPRANKS  ·  04-30
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Alterity Therapeutics (OtherPRNAF)
Stock Track | PROCEPT BioRobotics Soars 15.15% After-Hours on Strong Q1 Earnings Beat and Upbeat Guidance
Stock Track  ·  04-30
Stock Track | PROCEPT BioRobotics Soars 15.15% After-Hours on Strong Q1 Earnings Beat and Upbeat Guidance
Procept BioRobotics Q1 net loss widens 28% to $31.6 million; revenue rises 20% to $83.1 million
Reuters  ·  04-30
Procept BioRobotics Q1 net loss widens 28% to $31.6 million; revenue rises 20% to $83.1 million
Stock Track | PROCEPT BioRobotics Plummets 7.43% Intraday on Q1 2026 Earnings Results and Outlook
Stock Track  ·  04-30
Stock Track | PROCEPT BioRobotics Plummets 7.43% Intraday on Q1 2026 Earnings Results and Outlook
PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate
Benzinga  ·  04-30
PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate
BRIEF-Procept Biorobotics Q1 Revenue USD 83.132 Million Vs. IBES Estimate USD 80.5 Million
Reuters  ·  04-30
BRIEF-Procept Biorobotics Q1 Revenue USD 83.132 Million Vs. IBES Estimate USD 80.5 Million
Procept Biorobotics Q1 EPS USD -0.56
THOMSON REUTERS  ·  04-30
Procept Biorobotics Q1 EPS USD -0.56
Procept Biorobotics Outlook FY Revenue Growth 27-33%
THOMSON REUTERS  ·  04-30
Procept Biorobotics Outlook FY Revenue Growth 27-33%

Introduction

Company Name.
PROCEPT BioRobotics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Issue price:
--